Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -31.02
- Piotroski Score 1.00
- Grade Neutral
- Symbol (VIRI)
- Company Virios Therapeutics, Inc.
- Price $0.16
- Changes Percentage (12.4%)
- Change $0.02
- Day Low $0.14
- Day High $0.21
- Year High $26.00
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.27
- Trailing P/E Ratio -0.84
- Forward P/E Ratio -0.84
- P/E Growth -0.84
- Net Income $-5,296,015
Income Statement
Quarterly
Annual
Latest News of VIRI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Enviri Corp (NYSE:NVRI): A Bull Case Theory
Enviri Corp (NVRI), formerly Harsco, is a standout in waste management and recycling, offering comprehensive services to global clients. Despite challenges, its strategic initiatives and potential for...
By Yahoo! Finance | 1 month ago -
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
Viridian Therapeutics released positive data from the THRIVE phase 3 trial of VRDN-001 for thyroid eye disease. Veligrotug showed significant improvements in key disease endpoints, with promising resu...
By Yahoo! Finance | 1 month ago -
Viridian Therapeutics Shares Rise on Positive Results of Veligrotug in Thyroid Eye Disease Trial
Viridian Therapeutics stock surged before market open following positive phase 3 trial results for their thyroid eye disease treatment. The VRDN-001 treatment showed significant efficacy and safety in...
By MarketWatch | 1 month ago
